The company’s refocus on COVID-19 and 1L STK11m NSCLC sees relapsed AML being deprioritized, but not discontinued. The strategic shift will likely see more resources allocated to the prioritized indications, increasing the company’s probability to capitalize on the opportunities. This negatively affects estimates in the short term but might be more feasible in the long term. We reiterate our Buy recommendation with a NOK 27/sh TP.
